Highlights•HCV NS5A replication complex inhibitors.•Exceptional potency with broad
genotype coverage translated in clinical studies.•Important component for HCV combination …

Increased accumulation of cytoplasmic lipid droplets (LDs) in host nonadipose cells is
commonly observed in response to numerous infectious diseases, including bacterial …

Background & Aims The fixed-dose combination of sofosbuvir/velpatasvir was highly
efficacious in patients infected with genotype (GT) 1–6 hepatitis C virus (HCV) in the …

The hepatitis C virus (HCV) nonstructural 5A (NS5A) phosphoprotein has been intensely
studied due to its ability to subvert the host interferon-induced antiviral response. However …

The nonstructural protein NS5A has emerged as a new drug target in antiviral therapies for
Hepatitis C Virus (HCV) infection. NS5A is critically involved in viral RNA replication that …

Two classes of hepatitis C antiviral agents currently exist, ie, direct-acting antivirals and host-
targeting antivirals. Direct-acting antivirals target viral proteins including NS3/NS4A …

Mitophagy is a selective form of autophagy, targeting damaged mitochondria for lysosomal
degradation. Although HCV infection has been shown to induce mitophagy, the precise …

The hepatitis C virus (HCV) causes chronic hepatitis by establishing a persistent infection.
Patients with chronic hepatitis frequently develop hepatic cirrhosis, which can lead to liver …

Background Data on persistence of NS5A resistance-associated substitutions (RASs) may
have implications for resistance testing approaches and selection of initial and retreatment …

Despite the success of direct-acting antiviral (DAA) agents in treating chronic hepatitis C
virus (HCV) infection, the number of cases of HCV-related hepatocellular carcinoma (HCC) …